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This study was performed to analyze the eff ects of tunicamycin (TM) and taurohyodeoxycholic acid 
(TUDCA) on THLE-3 cells. Cells were treated with TM to induce endoplasmic reticulum (ER) stress and 
TUDCA was administered as an ER stress inhibitor. Cytotoxicity was evaluated at diff erent times of expo-
sure by incubating cells with increasing concentrations of either TUDCA, TM or both. THLE3 cells were 
cultured in fi bronectin, bovine collagen I and bovine serum albumin coated plates. Cell lines were grown 
in BEGM media supplemented with epidermal growth factor, phosphoethanolamine, fetal bovine serum, 
100 U of penicillin-streptomycin and maintained in a humidifi ed incubator at 37°C and a 5% CO2 atmo-
sphere. Cell viability was measured using the colorimetric 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetra-
zolium bromide (MTT) assay kit. Cells were grown to confl uence in 96-well plates and incubated with 1 
μl/ml DMSO, 1–10 μg/ml TM, 0.1-5 mM TUDCA, or 10 μg/ml TM + 0.1-1 mM TUDCA for 18–48 h. Control 
cells were prepared in plates containing only medium. At the end of the incubation period, MTT was 
added to each well and incubation was carried out for 4 h at 37 °C. Formazan production was expressed 
as a percentage of the values obtained from control cells. At all hours of incubation neither DMSO nor 1 
mM TUDCA was cytotoxic. At 24 and 48h incubations 5 mM TUDCA and 10 μg/ml TM + 1 mM TUDCA 
were signifi cantly cytotoxic compared to control, DMSO and 1 mM TUDCA groups. Treatment of cells 
with 0.5 mM TUDCA 8h before administrating 10 μg/ml TM signifi cantly decreased the cytotoxic eff ect of 
TM. We conclude that TUDCA may show cytotoxic eff ects at 1 mM concentration when treated with TM. 
Therefore 0.5 mM of TUDCA, administered 8h before TM treatment should be applied to protect against 
ER stress.
This study was supported by a grant from The Scientifi c and Technological Research Council of Tur-
key (TUBITAK; 214S223).
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Myeloproliferative neoplasms (MPN) are a class of stem cell–derived hematologic malignancies, 
characterized by an expansion of one or more myeloid lineages with resulting bone marrow (BM) hyper-
cellularity. A gain-of-function mutation in JAK2, detected in most patients with MPN, induces constitutive 
activation of JAK2, stimulation of downstream signaling pathways, and activation of several cytokine and 
growth factor genes. Recently we have reported that the BM of Primary myelofi brosis (PMF) patients har-
bors more neoplastic functionally distinct fi brocytes and fewer mesenchymal stromal cells (MSCs) than 
hematologically normal BM. In addition, we detected an overabundance of fi brocytes in the BM and spleen 
of an established PMF mouse model and a xenograft mouse model of PMF created using BM-derived low-
density cells from patients with PMF. Fibrocytes, spindle-shaped fi broblast-like cells that diff erentiate 
from a subpopulation of CD14+ monocytes, are associated with evolving tissue fi brosis, such as pulmo-
nary fi brosis, end-stage liver or kidney disease, heart disease and autoimmune disorders. Here, we show 
the dysregulation of microRNAs (miR-16, -21, -29a, -29b1, -29b2, -29c, -155, -181a, and -451) in cultured 
fi brocytes from BM of PMF patients. Bone marrow mononuclear cells (MNC) from twenty eight primary 
myelofi brosis patients and nine BM normal controls were cultured. The resulting fi brocytes were used for 
present study. Using qRT-PCR we found that expression levels of miR-16 (p=0.0122), and miR-21 were 
higher in MF patients than in normal controls. Expression level of miR-29-b1 and -b2 levels were signifi -
cantly lower (p=0.0007, p=0.0001) in MF patients; however, the miR29-c level was higher (p=0.0028). Dys-
regulation of miR-29 has been associated with coronary artery fi brosis and we conclude that miR-29 might 
play a role in bone marrow fi brosis and represent a potential therapeutic target.
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Pulmonary neuroendocrine (NE) tumors form a distinct group of neoplasms that share characteristic 
morphologic, immunohistochemical, ultrastructural, and molecular features. The clinical spectrum is var-
ious, from low-grade typical carcinoid (TC) and intermediate-grade atypical carcinoid (AC) to high-grade 
large cell NE carcinoma (LCNEC) and small cell lung carcinomas (SCLC). However, they represent a wide 
spectrum of phenotypically distinct entities, from which pulmonary NE tumors can sometimes be diffi  cult 
to diff erentiate, even for an expert pathologist. miRNAs, short non coding RNAs (18-21nt), are a promis-
ing new class of cancer biomarkers which may potentially aff ect all aspects of clinical care from early 
detection, diagnosis, and prognosis. miR-375 was markedly induced by ASH1 in lung cancer cells where 
it was suffi  cient to induce NE diff erentiation. On the other hand miR-192 is known to show a high vari-
ability among solid tumors. In the present study we analyze miR-375 and miR-192 expression in a series 
of surgically resected NE lung tumors, including TC, ATC, LCNEC, SCLC, ADC and SQCC. The two aims 
of the study are 1) to verify whether there are diff erences in the expression levels of these putative markers 
in NE versus non-NE lung tumors, and 2) to verify the miRNAs diff erential expression within the diff erent 
subtypes of NE lung tumors.
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Bioelectricity represents endogenous electrical signaling via ion channels and pumps at the plasma 
membrane, which shapes unique patt erns of voltage potentials across the membranes. Resting membrane 
potential (Vm) is a functional determinant of cell behaviour. There is a functional relationship between 
resting membrane potential (Vm) and cell proliferation and diff erentiation, which can be seen in many 
cells including normal stem cells and various tumors. Sundelacruz et al. (Tissue Eng Part A 2013) have 
shown that Vm depolarization promotes maintenance of mesenchymal stem cells in an undiff erentiated 
stage. We postulated that depolarized Vm may also help to maintain a population of cancer stem cells 
(CSCs) in undiff erentiated, but highly invasive state. Cancer stem cells (CSCs) represent a subpopulation 
of cancer cells responsible for tumor formation, relapse and metastasis. The breast CSC model used in this 
study consists of cells with up-regulated Twist expression (HMLETwist), which are showing markers of 
CSCs and have functional CSC properties. 
Therefore, Vm was measured by Nystatin-perforated Patch-Clamp method in a breast CSC model. 
Also, we measured Vm of SUM159 and MCF7, two breast cancer cell lines with high and low percentage 
of CSCs among whole population, respectively. Furthermore, we used proprietary potassium ionophores, 
previously shown to be highly cytotoxic for breast CSC model cells, to modulate membrane potential. 
Membrane potential after treatment with compounds was estimated using the cationic dye DiOC6(3).
It was indeed shown that SUM 159 cells are more depolarized than MCF7. Regarding breast CSC 
model, there was no diff erence in Vm between HMLEtwist and control HMLE cells, pointing to potential 
limitations of this model. 
Two highly cytotoxic proprietary potassium ionophores modulated membrane potential in breast 
CSC model. Although related by structure, one depolarized, while other hyperpolaryzed cells. Compound 
613 causes severe depolarization in HMLEtwist cells. Electrophysiological measurements pointed that 
compound at fi rst hyperpolarizes cells, which is followed by depolarization. Mode of action of both com-
pounds is under investigation.
Measurements of resting potential in CSCs with and without modulators will be further investigated.
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Caveolin-1 (CAV1), a structural protein of caveolae, directly interacts with multiple proteins that play 
role in diff erent physiological signaling. Thus, the genetic and epigenetic patt ern of CAV1 gene could be an 
important factor for normal and pathological conditions. The expression of CAV1 gene is quite in diff erent 
in normal and cancer brain tissues. The regulation mechanism of CAV1 expression is unknown in brain. 
Methylation could be regulatory mechanism of CAV1 gene and CAV1 methylation status may be an impor-
tant factor in terms of clinic parameters in Glioblastoma (GB). There is not any published study about 
CAV1 methylation and clinical importance.
The aim of this study is to investigate CAV1 gene promoter methylation patt ern in normal and cancer 
tissues of GB patients.
The tumor and normal tissues from 43 patients with GB were included in this study.
Genomic DNA was isolated from all tissues. After bisulfi te modifi cation of gDNA, MS-PCR tech-
niques were performed to identify of the CAV1 methylation status in tissues. Amplifi ed PCR products 
were visualized on 2.5% agarose gels. Clinic information and CAV1 methylation status are compared for 
the eff ect on patients’ survival, resistance to chemotherapy and recurrence of the tumor.
The rate of unmethylation and methylation of CAV1 gene promoter were found at 58.1%, and 41.9% 
in tumor samples, while it was present at 76.5% and 23.5% in normal tissues, respectively. In two patients, 
while normal samples have UM (hemimethylated) patt ern of CAV1 gene tumor samples have UU (unmeth-
ylated) patt ern. Likewise, in other two patients, while normal samples have UU patt ern, tumor samples 
have UM patt ern. Not detected MM (full methylated) patt ern in tumor and normal tissues. There is no any 
statistical signifi cance between methylation and recurrence, chemotherapeutic resistance in patients 
(p>0.05). 
CAV1 is initial protein for several signalling pathway and thus it has an important role in cells. Epi-
genetic and genetic patt ern of CAV1 may directly aff ect the cell’s destiny. Our study is fi rst report showed 
that CAV1 promoter methylation in GB patients. When clinical eff ect of CAV1 methylation was assessed, 
all assays should be studied in both normal and tumour tissues in the same patients because this study 
showed that GB patients have genetic heterogeneity in terms of CAV1 methylation. According to our 
results, the epigenetic eff ects of CAV1 gene can be cell type specifi c. 
The epigenetic elements (methylation, miRNAs and acetylation) for CAV1 gene should be studied in 
brain tumours. This is the fi rst report that investigated the Caveolin-1 promoter methylation and its clini-
cal eff ects in GB.
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Survivin, encoded by BIRC5 gene, belongs to the family of inhibitors of apoptosis (IAP) proteins. 
Although its expression is usually confi ned to G2-phase and mitosis, survivin is often expressed through-
out the cell cycle in cancer. In healthy organisms it is not expressed in diff erentiated tissues, while its 
expression is markedly increased in tumors. Its abundance in tumors correlates with increased resistance 
to chemotherapy and radiation, treatments lethal to cells through DNA damage and apoptosis induction. 
BIRC5 polymorphisms have been previously associated with increased expression, stability and localiza-
tion of survivin, that all can aff ect tumor development.
At least 5 diff erent splice variants of the survivin gene have been reported in humans so far (wild 
type, 2α, 2B, 3B and deltaEx3). All survivin protein isoforms arising from the splice variants share the same 
N-terminus region, including either part or the entire Baculovirus IAP Repeat (BIR) domain, but they dif-
fer in the carboxyl end. The transcript expression levels of various survivin isoforms have been signifi -
cantly associated with clinico-pathologic characteristics in several cancers.
In this study we investigated the role of BIRC5 polymorphisms and survivin gene expression in ovar-
ian cancer. Genetic testing of 40 patients and 74 healthy controls was conducted using high resolution 
melting analysis and Sanger sequencing. Fifteen diff erent polymorphisms were found in ovarian carci-
noma samples, 9 common and 6 rare. The distribution of polymorphisms did not diff er between healthy 
controls and ovarian carcinoma samples. 
For 22 patients that had RNA of suffi  cient quality, the expression of fi ve splice variants was deter-
mined using qPCR. The highest expression of all splice variants was of survivin 2α, then wild type sur-
vivin, followed by survivin deltaEx3 and survivin 3B. The lowest expression was of the splice variant 
survivin 2B, which was expressed in only 15 of 22 samples analyzed. All splice variants had higher expres-
sion in ovarian cancer compared to healthy Fallopian tube tissue.
For three polymorphisms (c.-1547C>T, c.9386T>C and c.10611C>A), homozygous major genotype 
showed higher expression of wild type, 2α, 2B and 3B isoforms compared to heterozygous genotype. Fur-
thermore, major allele of the same polymorphisms showed higher expression of wild type, 2α and 2B 
isoforms compared to minor allele.
This was the fi rst study in Croatia which correlated BIRC5 polymorphisms with the level of its splice 
variants expression. Our results have also demonstrated a possible role of BIRC5 polymorphisms in ovar-
ian cancer etiology, and their potential as prognostic biomarkers.
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Cancer stem cells (CSCs) are regarded as a leading cause of cancer relapse due to their ability to 
reconstitute tumour’s heterogeneity even after its eradication. It has been suggested that CSC resistance to 
chemo- and radiotherapy could be related to enhanced survival pathways, decreased levels of reactive 
oxygen species and increased expression of drug effl  ux pumps. Nevertheless, related molecular mecha-
nisms remain elusive. Recent research has pinpointed salinomycin, a naturally occurring potassium iono-
phore, as a promising compound for targeting CSCs. Moreover, several studies indicate that one of the 
mechanisms of action of salinomycin towards CSCs is the inhibition of P-gp drug effl  ux pump activity. 
Pertaining to the mentioned studies and results previously published by our group regarding anti-
cancer activity of proprietary crown ethers that act as K+ ionophores, we hypothesized that these com-
pounds could show selectivity towards CSCs. Therefore, we set about to elucidate their mechanism of 
action, with the focus on the eff ect towards the function and activity of drug effl  ux pumps.
To evaluate the impact of proprietary crown ethers on cancer cells with respect to P-gp expression, 
multidrug resistance model cell lines A2780 and A2780/Adr were used, latt er having overexpressed P-gp. 
Cytotoxicity evaluated by MTT assay showed increased resistance of A2780/Adr cells to P-gp substrates 
(e.g. doxorubicine, paclitaxel), as expected. Moreover, in order to assess the functional activity of P-gp, 
rhodamine effl  ux assay was performed. Obtained results showed strong inhibition by proprietary com-
pounds, while combined treatment with paclitaxel indicated cell sensitization towards this chemothera-
peutic. These results were further confi rmed by cell cycle analysis and annexin V assay. Additionally, 
implications of crown ether molecular mechanisms of action were obtained by analysis of the impact of 
these compounds on P-gp expression and upstream regulators of this drug effl  ux pump. 
Results indicate stronger P-gp inhibition obtained by proprietary crown ether treatment than by the 
commercially available P-gp inhibitor, verapamil. Additionally, plausible molecular mechanisms of action 
of crown ether compounds will be presented.
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Nanoparticle-based therapies to treat cancer are widely evolving. Gold nanoparticles (GNPs) are 
small units that are inert and non-toxic to cells. The aim of this work was to study the radiosensitization 
eff ect of three types of GNPs to MDA-MB-231 breast cancer cells in vitro. Citrate, glutathione and amino-
dextran were used to modify GNPs surface and to increase their accumulation in cancer cells. All GNPs 
were well characterized with respect to their particle size, shape and colloidal stability in aqueous solution 
and cell media. Transmission electron microscopy demonstrated accumulation of GNPs in cytoplasmic 
vesicles, while the mass spectroscopy demonstrated the highest uptake of glutathione modifi ed GNPs. 
GNPs alone show no signifi cant eff ect on cell cycle demonstrated by fl ow cytometry and western blot 
analysis. As well, cells treated with GNPs in combination with x-ray irradiation show no signifi cant eff ect 
on cell cycle. Nevertheless, long-term overall survival of cells treated with GNPs in combination with irra-
diation was reduced. In conclusion, we showed that GNPs have certain biological eff ect, but still the pre-
cise mechanism of their activity remains to be explored.
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In the present study the expression patt erns of critical molecular components of Wnt signaling path-
way – sFRP3 and DVL3 protein were investigated in 34 glioblastoma patients.
Immunostaining and Image J analysis revealed the quantity and subcellular localization of the pro-
teins. The protein expression levels in tumor tissue were evaluated by the semiquantitative method in the 
3-stage signal strength and immunoreactivity score (IRS). Majority of glioblastomas had moderate levels 
of expression for both DVL3 (52.4%) and sFRP3 (52.3%). Strong expression levels of DVL3 and sFRP3 pro-
teins were observed in 23.1% and 36.0% of samples, respectively. DVL3 was localized in cytoplasm in 97% 
of glioblastoma, of which 44% coexpressed the protein in the nucleus. The analysis of sFRP3 protein’s 
subcellular distribution showed that it was localized in the cytoplasm in 94% of cases. Colocalization in the 
cytoplasm and nucleus was observed in 50% of samples. No signifi cant correlation between DVL3 and 
sFRP3 mutual expression was established, nor were signal strengths correlated with epidemiological 
parameters. Wilcox test indicated that the domination of the strong signal in cells is in connection with 
simultaneous localization of DVL3 protein in the cytoplasm and the nucleus. Patients with strong expres-
sion of DVL3 will signifi cantly more often have the protein in the nucleus (P=6.33x10-5). Strong signal for 
sFRP3 did not show such an association. 
Our study shows that dynamic changes in the expression levels and localizations of the studied pro-
teins may infl uence the activtion of Wnt signaling in glioblastoma. These fi ndings may contribute to bett er 
understanding of glioblastoma molecular profi le.
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Upper urinary tract urothelial cancers (UUC) are rare in general population but occur in almost 50% 
of patients with endemic nephropathy (EN)/aristolochic acid nephropathy (AAN). Aristolochic acid (AA) 
was proven as the etiological factor both for EN/AAN and UUC. The goal of this study was to identify 
tumor suppressor genes and oncogenes involved in AA induced carcinogenesis and their postt ranscrip-
tional regulation mehanisms by microRNAs.
 Paired samples of tumors and adjacent normal urothelial tissues of 13 patients from Croatian and 
Bosnian endemic regions were analyzed. MiRNA profi ling was performed by high-capacity quantitative 
PCR, while mRNA expression profi ling of the same RNAs was done using microarray technology. Immu-
nohistochemistry was performed on tissue microarrays. 
The broad involvement of known cancer genes in the process of UUC tumorigenesis was revealed by 
expression profi ling analysis of the tumors, implicating on many oncogenes (35 up-regulated; 54 down-
modulated), and known tumor suppressor genes (17 up-regulated; 3 down-modulated). We studied 
whether the upregulation of specifi c oncogenes (MYC, FGFR3, HRAS and KRAS) and down regulation of 
tumor suppressor genes (PTEN and PTCH1) might be augmented in UUC by coordinated action of miR-
NAs. Our results showed a correlative network implicating numerous down-modulated miRNA regula-
tors of these oncogenes, including tumor suppressor miRNAs miR-23b, miR-143 and miR-145, and also a 
broad inhibition of PTCH1 by increased oncogenic miRNAs including miR-21, miR-18a and miR-9, and of 
PTEN by oncogenic miRNAs of the miR-17-92 family. Both PTEN and PTCH1 appear commonly inhibited 
by essentially all the members of the miR-200 family. The elevated MYC then represents a central node in 
these processes, functioning as the activator of miR-17, miR-20 and miR-9 and inhibitor of miR-23b, the 
repressor of FGFR3 and KRAS, and the tumor-suppressor miRNA let-7c. By means of immunohistochem-
istry a trend of lower expression of PTEN protein was observed in tumor versus the normal tissue. 
AAN-associated UTUC carcinogenesis is characterized by a major deregulation of oncogenes and 
tumor suppressor genes, whose activity may be broadly modulated by coordinate action of miRNAs ulti-
mately aff ecting the UUC-specifi c protein levels.
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Sonic Hedgehog (SHH) protein, along with Indian Hedgehog (IHH) and Desert Hedgehog (DHH), is 
a ligand that activates Hedgehog signaling pathway (HH). It is an evolutionary conserved pathway that is 
necessary for normal embryonal development of diverse organisms, from fruit fl ies to humans. Whereas 
in adult human cells HH is largely inactive, it may become active following various tissue injuries that 
require reparation and regeneration of damaged cellular structures. Disruption in activation of this signal-
ing pathway has been found in many types of human cancers indicating its important role in carcinogen-
esis. Since SHH is one of the activators of HH signaling pathway, the aim of this study was to defi ne the 
patt ern of SHH protein expression. This is essential for bett er understanding of proliferative, migratory 
and invasive potential of cells of human ovarian high-grade serous carcinoma and human ovarian benign 
serous tumors. Thus, expression of SHH ligands was analyzed by immunohistochemistry and quantifi ed 
using stereological method of tissue volume density (Vv; mm0) estimation. We found statistically higher 
expression of SHH ligands in ovarian high-grade serous carcinoma (0.1122±0.01590) compared to ovarian 
benign serous tumors (0.02917±0.003564) (Mann-Whitney test; p=0.0002), which indicates an increased 
activation of Hedgehog signaling pathway in carcinomas with high malignant potential. This result, i.e. an 
association between increased expression of SHH proteins and development of aggressive ovarian malig-
nancy, points to potential important role of HH signaling pathway in ovarian tumorigenesis.
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Renal cell carcinoma (RCC) represents 2-3% of all cancers, with the highest incidence in Western 
countries. Over the last two decades the incidence of RCC is increased by 2%, mostly due to increased 
detection of tumors by ultrasound and computed tomography. It is accepted that prognosis of RCC diff ers 
according to the histological type, nuclear grade and tumor stage. In some cases these prognostic factors 
are not suffi  cient to predict clinical outcome of RCC. New molecular prognostic factors are being evalu-
ated and, accordingly, the prognostic value of TP53 tumor supressor gene has been investigated. The p53 
tumor suppressor is classifi ed as “guardian of the genome” since it is critical in the control of cell growth 
and the maintenance of genomic stability. TP53 encodes 12 diff erent isoforms and the sum of their activi-
ties determines the p53-mediated cell response. The expression of p53 isoforms has been shown to be 
dysregulated in several human cancer types. In this study we have analyzed mRNA expression of p53, 
∆40p53 and ∆133p53 isoforms in 42 renal cell cancers and matched normal adjacent tissues by real-time 
PCR, and analyzed their expression in relationship to clinical features and outcome.
The overexpression of Δ133p53 was observed in the RCC tissues, and it was expressed at levels 
approximately two times higher than the median expression of p53 and ∆40p53. Moreover, the high 
expression of Δ133p53 correlated with short overall survival (P=0.027). Relative expression of each isoform 
in the tumors highly correlated with one another. In tumors, ∆40p53 mRNA and ∆133p53 mRNA were 
expressed at levels signifi cantly higher (2.3-times ∆40p53, 3.5-times ∆133p53) then the median expression 
of matched normal adjacent tissues. We have also determined that ∆40p53 expression was negatively asso-
ciated with invasion of kidney capsule and positively associated with disease free survival, suggesting 
that high levels of ∆40p53 are protective.
In conclusion, Δ133p53 is overexpressed in RCC tissue and the high expression of Δ133p53 is corre-
lated with short overall survival. Future clinical studies are needed to investigate function of p53 isofoms 
and their relationship to clinical features and outcome in patients with renal cell carcinoma.
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Most methylating enzymes use AdoMet as methyl group donor to methylate their substrate. AdoHyc 
is additional product of transmethylation reactions and is also proven to be one of the strongest competi-
tive inhibitors of methyltransferases. Proper activity of AHCY hydrolase is therefore essential for fast 
removal of AdoHyc in order to avoid global alterations of cell methylation. Recently, it has been reported 
that level of AHCY hydrolase expression might have impact on changes in cell characteristics usually 
associated with so called cancer phenotype: cell cycle regulation, cell proliferation and migration. To 
investigate possible changes, targeted silencing of AHCY hydrolase in hepatocellular carcinoma cell line 
was performed using shRNA. Libraries for transcriptome sequencing were prepared automatically on 
NeoPrep Library System with TruSeq Stranded mRNA Library Prep Kit and sequenced on NextSeq desk-
top with integrated Basespace Sequence Hub platform (Illumina) for automatic data streaming, demulti-
plexing and fi ltering. Comparative proteomics was performed by Stable Isotope Labeling by Amino acids 
in Cell culture (SILAC) and liquid chromatography – mass spectrometry (Orbitrap Velos Pro). All datasets 
were analyzed and compared using IPA software (QIAGEN) to investigate potential biomarkers and 
assess changes in cellular mechanisms, pathways and functions. Additionally, metabolic cell activity was 
measured by MTT viability test and Neutral red uptake assay to analyze diff erences in cell proliferation, 
while transwell chamber assay was used to study changes in cell migration. We found that metabolic activ-
ity tests show decrease and indicate reduced cell proliferation. Also, slower cell migration is seen using 
transwell assay. IPA analysis confi rmed these results and predicted that cell cycle is aff ected through sev-
eral checkpoints leading to possible cell cycle arrest. Progression to cancer phenotype usually starts with 
alterations of cell cycle since its control is necessary for preventing unrestrained cellular growth. Our 
research indicates complex changes in regulation of cell cycle after AHCY hydrolase silencing with com-
peting contribution of various pathways. Inhibitors of AHCY are currently being investigated as potential 
cancer treatments, thus understanding their eff ect on cell cycle is critical to predict possible treatment 
outcomes as well as for eff ective mixed drug therapies.
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BRAF mutations, which are found in 40–60% of all melanomas, are predictive marker for targeted 
therapy with BRAF-inhibitors in patients with metastatic melanoma. 80–90% of all BRAF mutations in 
melanoma are V600E and next in frequency (10-20%) is V600K. The aim of this study was to determine the 
frequency of V600E and V600K BRAF mutations and association between gender, age and type of sample 
material (primary melanoma or metastasis) with presence and type of BRAF mutation in melanomas from 
patients treated at University Hospital Sestre milosrdnice, Croatia. To our knowledge this will be the fi rst 
such study for Croatian population.
DNA was isolated from archived formalin-fi xed paraffi  n-embedded (FFPE) melanoma tissue and 
assayed by real-time PCR for BRAF V600E and BRAF V600K mutations using specifi c TaqMan probes. For 
statistical analysis Mann-Whitney U test or χ2 test were used, depending on type of variable.
A total of 189 samples (57 primary melanomas, 132 metastases) from 177 patients (97 male, 80 female; 
age 21-89 years, median 62 years) were analysed. Among 189 samples, 54% had BRAF mutation (11% 
V600K and 43% V600E), 41% did not have BRAF mutation, and 9 (5%) were inadequate for the analysis. In 
8 patients two diff erent lesions (primary melanoma and metastasis or 2 diff erent metastases) were anal-
ysed and in one of these patients results were discordant, primary melanoma had V600E mutation and 
metastasis did not have BRAF mutations. Patients with BRAF mutations were signifi cantly younger than 
patients without BRAF mutation (median age 59 and 67 years, p=0.0005). Among patients with BRAF 
mutation, the ones with V600E mutation were signifi cantly younger than the ones with V600K mutation 
(median age 56 and 71 years, p=0.0001). Frequency of BRAF mutations was signifi cantly higher in male 
patients than in female patients (p=0.001). Frequency of BRAF mutations was signifi cantly higher in sam-
ples from metastases than in samples from primary melanoma (p=0.032). 
Frequency of BRAF V600E and V600K mutations and association with age shown in our patients is 
concordant with previously published results in other populations of melanoma patients. Discrepancy in 
BRAF mutation status between primary melanoma and metastasis shown in one patient warrants that 
inter-lesional heterogeneity should be taken into account while interpreting BRAF mutation analysis 
results.
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Testicular Germ Cell Tumours (TGCT), although rare, are the most frequent malignancies in young 
male population and believed to be initiated by epimutations, i.e. aberrant epigenetics, already in utero. 
Among various, teratoma is the most diff erentiated TGCT type encompassing all three germ layer derived 
tissues. Mouse teratoma is a well-established in vitro model which may be obtained by cultivating 7,5-days-
old C3H mouse embryos and represent an ideal system to investigate the eff ect of the most prominent 
epigenetic drugs and agents. 
After embryo isolation, they were treated for two hours with 5-azacytidine, Trichostatin A, Valproat, 
esiNanog, esiOct3/4 and esiTrrap, respectively. Embryos/teratomas treated with esiGFP served as a nega-
tive control. The embryos/teratomas were measured on day 0 and for the consequent 7 days of culturing, 
after which teratomas were scrapped, Sainte-Marie fi xed and paraffi  n embedded for IHC analyses. 
Epigenetic drugs and agents reduced signifi cantly teratoma growth, all except esiNanog and esi-
Trrap. Most prominent decrease in growth was determined in 5-azaC and esiOct3/4 treated embryos/tera-
tomas.
IHC analysis of proliferative activity showed signifi cant rise in Ki-67 signal in esiNanog and esiTrrap, 
but in 5azaC treated as well, compared to control. Apoptotic activity showed no signifi cant change in any 
treatment. 
This preliminary data notify that epigenetic drugs and agents may have a signifi cant eff ect on embryo/
teratoma growth. It seems that teratoma growth is inhibited by necrotic activity rather than apoptosis 
which could consequently induce a rise in proliferation as a tissue reaction.
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Cancer stem cells (CSC) are an immortal tumor-initiating population that can selfrenew and has plu-
ripotent capacity. Despite their small number, CSCs are believed to be critical for tumor initiation, progres-
sion and metastasis, as well as for the treatment failure and disease relapse. CSCs have been confi rmed to 
exist in various types of tumors which include leukemia as well as solid cancers. There are several obsta-
cles involved with CSC research among which are their low number within tumor cell population and 
their relative instability in culture. Recently, a breast CSC model was established by experimental induc-
tion of epithelial to mesenchymal transition (EMT) in immortalized human mammary epithelial cells 
(HMLE). Using this model salinomycin was identifi ed to be selectively toxic towards epithelial CSCs. 
Salinomycin is a K+/H+ exchanger that can aff ect cation transport across diff erent membranes present in 
the cell. However the exact mechanism of the observed selectivity remains largely unknown. We have 
noticed that salinomycin aff ects potranslational modifi cations of membrane proteins in the fore mentioned 
CSC model. This led us to the hypothesis that salinomycin induces Golgi apparatus stress that aff ects 
secretory pathway which may represent a key vulnerability of EMT cells. Of note, monensin, another 
ionophore with chemical structure similar to that of salinomycin, is a well described inhibitor of Golgi 
function.
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Breast cancer is the most common cancer in women worldwide and the incidence continues to rise in 
many countries. Due to potential of recurrence of this disease, it is important to fi nd a molecular marker 
helping in prediction of late recurrence. Metastasis associated in colon cancer 1 (MACC1) was fi rst identi-
fi ed to be over-expressed in primary and metastatic tumor specimens of colon cancer. MACC1 has also 
been found to stimulate proliferation, motility and invasion in colon cancer cells. To our knowledge lim-
ited information regarding MACC1 function in late recurrence of breast cancer. Western blot analysis of 
MACC1 was conducted in 125 protein extracts of mammary carcinoma and evaluated by densitometry. In 
addition, ten formalin fi xed and paraffi  n embedded samples of breast- and ovarian cancer were analyzed 
for in situ localization of MACC1 by immunohistochemistry (IHC). Obtained results showed no statistical 
signifi cance of MACC1 expression in the entire tested patient cohort. However, within the lymph node 
negative (p<0.05) and estrogen receptor positive (p<0.05) subgroups, a signifi cant association between 
high MACC1 expression and shorter disease-free survival was observed. Furthermore, no signifi cant sta-
tistical correlation between MACC1 and c-MET could be detected in tested patients. IHC results showed a 
positive MACC1 immunodetection. In conclusion, these results indicate a potential predictive/prognostic 
role of MACC1 in tested subgroups of ER (+) and lymph node negative breast cancer patients in later 
recurrence since these two subgroups are associated with favorable prognosis.
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Breast cancer is the most common cancer in women worldwide, and it is the leading cause of cancer 
related deaths in Croatia. Ovarian cancer is in the fi fth place, both in incidence and mortality. About 5-10% 
of all breast and/or ovarian cancer cases are hereditary, and heterozygous germline BRCA1/2 mutations 
are responsible for the majority of hereditary breast and/or ovarian cancers. In the most cases, the muta-
tions are small nucleotide alterations that lead to the truncation of BRCA1 or BRCA2 proteins or aff ect 
amino acids that are critical for its structure or function. Large rearrangements of BRCA1 gene and less 
often, BRCA2 gene have been described in recent years, but haven’t been found in Croatia so far.
Here we describe a case of a Croatian breast cancer patient with no apparent family history of cancer, 
who developed Her-2 positive breast cancer at the age of 29, and triple negative breast cancer at the age of 
33. Due to the young age of onset and the triple negative status (known to be connected with BRCA1 muta-
tions), she was referred for BRCA1 gene testing. No mutation was found by HRM or sequencing, but the 
deletion of exons 4-6 of the BRCA1 gene was determined with the Quantitative Multiplex PCR method and 
confi rmed with MLPA analysis. Long range PCR and subsequent sequencing showed the mutation to be 
10,257 bp long (NG_005905.2:g.107648_117905del10257).
To determine if the mutation was de novo, patients’ family was contacted. Mother and sister do not 
share the mutation, but the father died from the heart att ack at the age of 47. On the father’s side there was 
a history of cancer (lymphoma, uterine, colon and lung cancer), but not breast and/or ovarian cancer. No 
family member from the father’s side of the family was available for testing.
This deletion has been reported six times in the literature. In three cases the deletion size was not 
determined (Italy, Slovenia and USA) and in the other three cases (Denmark, Germany and Spain), the 
deletions had diff erent breakpoints than in this case. Since the reported deletions are diff erent then here, 
it cannot be excluded that this is a case of a de novo mutation, but since there is a history of cancer on the 
father’s side of the family it is far more likely that it is not the case, and the lack of breast and ovarian can-
cers is just a coincidence. The fact that there were several cases of uterine cancer in the family, and it is 
known to be caused by BRCA1 mutations also contributes to this conclusion. It is also worth to mention 
that mutation in our case is more than twice in size than any other deletion of exons 4-6 of BRCA1 gene yet.
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Ovarian carcinoma is the leading cause of death from gynecological malignancies in the Western 
world. Its high death rate is a result of the fact that most patients (>60%) are diagnosed in advanced stage 
of the disease. Our experience with ovarian cancer so far came out from the research on genetic (mutations 
and polymorphisms) and epigenetic (promoter methylation) mechanisms of Hedghog-Gli signaling path-
way in the development of various types of ovarian malignancies. The purpose of this study was to fi nd 
out which Hedgehog-Gli (Hh-Gli) signaling pathway genes could be potential targets of microRNA mol-
ecules (miRNAs) diff erentially expressed in high-grade serous ovarian cancer (HGSOC), which is the most 
malignant type and most diffi  cult to detect at an earlier stage.
We conducted a miRNA profi ling on 8 fresh-frozen high-grade serous ovarian cancer tissue samples 
using Agilent SurePrint Human miRNA Microarray Kit 8x60K which contains probes for 2,549 human 
miRNAs represented in miRBase database (Release 21.0). In addition, 8 healthy Fallopian tube samples 
were used as a control tissue to fi nd diff erentially expressed miRNAs, since this type of tissue is presumed 
origin of HGSOC (Reade et al., J Obstet Gynaecol Can 2014). Acquired miRNA expression data were ana-
lyzed using LIMMA and AgiMicroRna tools from R/Bioconductor software package. Resulting p-values 
were adjusted for multiple hypothesis testing based on false discovery rate by Benjamini-Hochberg 
method. Furthermore, on-line DIANA Tools (diana.imis.athena-innovation.gr) were used to fi nd which 
Hh-Gli pathway genes are experimentally proven or potential targets of observed diff erentially expressed 
miRNAs.
Data fi ltration (IQR > 0.1, FDR < 0.1, logFC > 0.58 and < -0.58) gave us a list of 55 miRNAs: 32 were 
up- and 23 were down-regulated in HGSOC. Out of 47 genes which are involved in Hh-Gli pathway in 
humans (according to the KEGG Pathway hsa04340), 35 are known targets for 27 over-expressed observed 
miRNAs, while 22 genes are known targets for 16 under-expressed miRNAs. In addition, 28 genes are 
potential targets for 26 up-regulated miRNAs while 24 are potential targets for 19 down-regulated miR-
NAs in HGSOC.
Our results highlighted several candidate miRNAs which we intend to verify and functionally con-
nect to Hh-Gli pathway genes in our future research. Enlightening the interplay between miRNAs and 
Hh-Gli signaling pathway genes in serous ovarian carcinoma pathogenesis could give us new information 
for bett er therapeutic approaches and early prevention programs.
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Platinum-based drugs have been predominantly used in chemotherapy for decades. However, due to 
their high general toxicity and development of tumour drug resistance, there is a constant need to synthe-
size new compounds with reduced side eff ects. Organometallic ruthenium complexes have already shown 
promising anticancer activity. In this research, we explored biological characteristics of newly synthesized 
(p-cymene)-ruthenium complexes 1 and 2, bearing phosphane ligands substituted with chiral or non-chi-
ral amino acid esters. Interestingly, unlike most of the previously synthesized complexes that are described 
as “platinum mimicking”, we showed that these ruthenium complexes bind to proteins instead of DNA, 
although their possible specifi c target remains unknown. Cytotoxic activity was investigated on human 
cervix carcinoma cell line (HeLa) using MTT assay. Four (2pG, 2pA, 2mG and 2mA) out of six synthesized 
metallated biconjugates showed signifi cant toxicity, with IC50 values of 5 to 30 μM. 2mG compound with 
average value of IC50 16 μM was selected for further biological characterisation. The higher level of toxic-
ity towards tumour compared to normal cell lines indicates its selective activity, important characteristic 
for potential medical use. Further, using fl ow cytometry and propidium iodide staining, it was detected 
that 2mG caused dose-dependent increase of SubG1 cell population, suggesting its ability to induce apop-
tosis. Decreased survival of HeLa cells pretreated with specifi c inhibitor of glutathione (GSH) synthesis, 
buthionine sulfoximine, and opposite eff ect obtained by pretreatment of cells with GSH precursor N-ace-
tyl-cysteine, indicates important role of GSH in HeLa cells response to investigated organometallic ruthe-
nium complexes. Since 2mG did not induce reactive oxygen species, the decreased survival of HeLa cells 
pretreated with the inhibitor of glutathione-S-transferase, ethacrynic acid, and inhibitor of multidrug 
resistance protein family, probenecid, emphasizes involvement of GSH in detoxifi cation of 2mG com-
pound. We speculate that ruthenium complexes bind protein-based biomolecules triggering further cell 
death. Based on the gained knowledge, the synthesis and development of next generation of tumour-
specifi c ruthenium-based complexes as potential anticancer drugs is expected.
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Soft tissue sarcoma (STS) encompasses a plenitude of malignant tumors of the connective tissue. Most 
of these tumors are very invasive and the response to chemotherapy and radiation is very limited. The 
mechanism of soft tissue sarcoma tumorigenesis is still unclear; therefore, they represent a major thera-
peutic challenge. Mutation of p53 is a common hallmark of cancer. It is mutated in more than 50% of 
human tumors. However, knowledge about the prognostic relevance of p53 mutations in STS is not com-
prehensive, and, according to our data, seems to be rare. Therefore, other mechanisms of p53 inactivation 
might be involved. As is already well accepted, p53 is expressed not only as full length, but also as iso-
forms, some of which inhibit wild-type p53. There are no studies that have examined the relative expres-
sion of p53 isoforms in STS so far. 
Here, we have analyzed the relative mRNA expression of the p53, Δ40p53, Δ133p53 (C-terminal iso-
forms), p53α, p53β and p53γ (N-terminal isoforms) in a panel of 5 STS cell lines, 26 STS specimens and 15 
matched normal adjacent tissues using real-time PCR. Further we have analyzed their relationship to the 
outcome of disease. We have found that almost all isoforms were expressed equally, only p53γ was 
expressed at a higher level compared to p53. Further, we have observed that all three N-terminal isoforms 
are positively correlated to each other, compared to C-terminal ones which were not correlated. Addition-
ally, higher p53β expression was signifi cantly associated with longer overall survival (OS) of patients, 
while there was a trend toward signifi cant association of higher Δ40p53 expression with longer OS. How-
ever, the higher Δ40p53 expression was positively correlated to reappearance of tumor with marginal 
statistical signifi cance. These results have shown the implications of p53 isoforms in development of STS 
and might provide the elucidation for deregulated p53 function in STS.
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Among all skin malignancies, melanomas represent a serious worldwide health problem. Early detec-
tion and diagnosis are the most important steps in successful treatment of all cancers. In the past few 
decades diagnosis for melanoma has greatly changed. At present, for treatment and prognosis are impor-
tant combinations of clinical and histopathological parameters. Current, tumor markers are based on the 
method of determination of antigens and generally exhibit reduced specifi city and sensitivity. For this 
purpose, new tumor markers are necessary to enhance and improve the diagnosis and prognosis of dis-
eases, and enable targeted therapy. Aim of this study was to localize and identify Metastasis Associated 
Colon Cancer 1 (MACC1) as a potential molecular marker for human melanoma samples and correlate the 
MACC1 expression in patients diagnosed with colorectal cancer, where MACC1 has already been demon-
strated as a potential molecular marker. For the purpose of this study formalin-fi xed and paraffi  n embed-
ded specimens of melanoma and colorectal cancer obtained from 20 patients were used. Obtained results 
indicated successful in situ localization and identifi cation of the expression of a targeted protein, indicat-
ing that the MACC1 is equally expressed in melanoma and samples of colorectal carcinoma. In addition, 
these results suggest the potential and important role of this particular biomarker in early diagnosis of 
melanoma cancer and possible development of targeted therapy for melanoma patients. In conclusion, 
positive immunodetection of MACC1 in analyzed melanoma samples was generally more associated with 
poor prognosis in patients, and therefore could be used as a potential predictive marker for progressive 
forms of melanoma.
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Increased lipid peroxidation and changes in antioxidative system in patients with premalignant 
lesions of the cervix indicates the importance of oxidative stress in early phase of carcinogenesis. Paraox-
onase 1 (PON1) is a calcium-dependent esterase, synthesized in the liver and secreted into the plasma 
where it is associated with HDL. PON1 possess antioxidant/antiatherogenic activity, and it removes carci-
nogenic radicals of lipid peroxidation in human body. Polymorphisms in coding (Q192R and L55M) and 
promoter (-108 C>T) regions of PON1 gene aff ect Paraoxonase 1 activity. We carried out this study in order 
to determine frequencies of Q192R, L55M and -108C>T polymorphisms in patients with premalignant 
lesions of the cervix.
Study included 65womens [37 (29-42) years] with a biopsy confi rmed diagnosis of cervical intraepite-
lial neoplasia (CIN). CIN1 had 18 patients, 23 had CIN2 and 24 had CIN3. 109 healthy volunteers [38 (32-
46) years] without any cervical or other disease were enrolled in the study as a control group. DNA was 
isolated from whole blood and polymorphisms were determined by PCR-RFLP procedure.
The analysis of PON1 gene polymorphisms in patient group showed following frequencies: 51% QQ, 
44% QR, and 5% RR for Q192R genotype; 43% LL, 43% LM, and 14% MM for L55M genotype; 35% CC, 
42% CT, and 23% TT for -108 C>T genotype. In the control group we found rather similar frequencies: 59% 
QQ, 33% QR, 8% RR for Q192R genotype; 40% LL, 42% LM, and 18% MM for L55M genotype; 30% CC, 
45% CT, and 25% TT for -108 C>T genotype. No signifi cant diff erences was found concerning examined 
polymorphisms between patients and healthy volunteers (Q192R, P=0.258; L55M, P=0.728; -108C>T, 
P=0.784).
Our results suggest that Q192R, L55M and -108C>T polymorphisms of pon1 gene is not a potential 
risk factors for cervical intraepithelial neoplasia. However this fi nding must be confi rmed by study con-
ducted on bigger sample size.
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Aberrant DNA methylation of promoter region CpG islands is associated with gene silencing and 
serves as an alternative to mutation-induced inactivation of tumor suppressor genes in human cancers. 
Chronic infl ammation and infection have been recognized among major risk factors for the most common 
types of cancer. Several lines of evidences are linking cancer, infl ammation and infection. Transcription 
factor nuclear factor-κB (NF-κB), major inducer of infl ammation is activated by many cancer risk factors 
(cigarett es smoke) and is constitutively active in most cancer. Activation and controlling mechanisms of 
infl ammation and infection are regulated by NF-κB and almost exclusively relied on receptors of innate 
immunity, known as Patt ern Recognition Receptors (PRR). Thus, suppression of these proinfl ammatory 
pathways may provide opportunities for both prevention and treatment of cancer. The aim of presented 
study was to evaluate methylation status of ASC/TMS1 (Apoptosis-associated speck-like protein contain-
ing a CARD/Target of methylation-induced silencing-1) and MYD88 genes (Myeloid diff erentiation pri-
mary response 88), key adaptor molecules in innate immunity signalling. Here we found that both MYD88 
and ASC/TMS1 exhibit reduced methylation status of promoter regions in tumor tissues from patients 
diagnosed with lung cancer, comparing to healthy tissue. These results were also confi rmed on protein 
level. Reduced methylation status in tumor tissue, of both MYD88 and ASC/TMS1, correlate with higher 
protein expression and vice versa. To confi rm our fi ndings on mRNA level we performed pathway-focused 
gene expression analysis of 84 genes involved in TLR and NOD signalling pathway using RT-qPCR 
approach (RT2 Profi lerTM PCR Array Human Infl ammasomes). We found that expression of MYD88 
mRNA in tumor tissue is unchanged compared to healthy lung tissue, while mRNA level of ASC, gene 
involved in infl ammasome formation, is up-regulated in tumor compared to healthy lung tissue. Also, we 
detected tumor specifi c cytokine profi le on mRNA level: up-regulation of cytokines as IL18 and IL1B and 
down-regulation of cytokines as IL12A, IL33 and IL6.
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Melanoma is the most aggressive form of skin cancer. Integrin signalling regulates numerous cellular 
vital processes in tumour cells. The goal of this study was to investigate the impact of integrin αv knock-
down on sensitivity to antitumor drugs, cell migration and invasion. Three human metastatic melanoma 
cell lines A375, RPMI-7951 and MeWo were used. Flow cytometry analysis using integrin-specifi c antibod-
ies showed that all three cell lines express comparable amounts of integrin subunit αv and heterodimer 
αvβ5. However, they diff er in expression of integrin αvβ3 which is highly expressed in A375 and RPMI-
7951 but almost absent in MeWo cells. The siRNA-directed integrin αv knockdown increased sensitivity 
of RPMI-7951 and MeWo cells to the microtubule-directed antitumor drugs paclitaxel and vincristine, 
decreased sensitivity of MeWo cells to cisplatin, and neither changed sensitivity of RPMI-7951 cells to 
cisplatin nor of A375 cells to any of the abovementioned drugs. In vitro transwell migration and invasion 
assays conducted in the RPMI-7951 cell line upon αv silencing resulted in a drastic inhibition of both, cell 
migration and invasion. Using the same assay migration could not be assessed in MeWo cells, which is in 
accordance with literature data showing their low metastatic potential. We have also analysed the involve-
ment of pERK1/2 signalling pathway in integrin αv sensitisation to paclitaxel. The integrin αv knockdown, 
as compared to control-siRNA transfected cells moderately decreased the total amount of pERK1/2. The 
lower amount was maintained during 72 hours of paclitaxel exposure. Approximately 60–70% of malig-
nant melanomas have a BRAF mutation that constitutively activates the B-Raf/MEK/ERK1/2 pathway. 
They are treated with the BRAF inhibitor vemurafenib. The BRAF V600E mutated RPMI-7951 cell line is, 
however, vemurafenib-resistant due to the overexpression of COT which activates ERK1/2 independent of 
BRAF. Therefore, we analysed the combined eff ect of integrin αv knockdown and vemurafenib, and 
showed that integrin αv knockdown increased sensitivity of RPMI-7951 cells to vemurafenib. Our results 
identify integrin αv as a potential target for melanomas not responding to vemurafenib therapy such as 
BRAF V600E mutated but vemurafenib-resistant (RPMI-7951) and BRAF wild type (MeWo) melanoma 
cell lines to paclitaxel. Also the integrin αv knockdown decreases metastatic potential in the highly meta-
static cell model of RPMI-7951 cells.
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Aim of this study was to extract total cellular mRNA from cytobrush-collected healthy and Human 
Papilloma Virus (HPV) infected cervical epithelial cells and analyze whether the samples obtained by 
regular Papanicolaou test or commonly known as Pap test can be used for gene expression analysis. Pap 
test represents a non-invasive way to obtain biological material from selected group of patients. A total of 
40 cervical specimens were previously tested for HPV infection. Following HPV testing, samples were 
submitt ed to extraction and purifi cation of total cellular RNA. Products after RNA extraction methods 
used in this particularly study could be visualized using 2% agarose gel electrophoresis; however right 
after the RNA purifi cation step no visible bands were detected. The RNA extraction from a cohort (n=40) 
of cytobrush-collected cervical epithelial cells, used in this particular study, couldn’t be accomplished 
with either of the two RNA extraction methods used. In conclusion RNA purifi cation represents a neces-
sary step for assurance of high quality extracted RNA in all gene expression analysis studies. Reliance on 
commercial kits only or misinterpretation of the results can lead to serious errors in the implementation of 
fi nal conclusions and/or to false positive test results, aff ecting the effi  cacy of particular testing. According 
to obtained results, the sample type used in this study was not suitable for the gene expression analysis.
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Obesity is strictly linked to changes in redox state; oxidative stress mainly results from positive energy 
balance that leads to excessive fat accumulation in non-adipose tissues, with subsequent development of 
obesity co-morbidities (Savini et al., Int J Mol Sci 2013). The aim of this study was to explore the impact of 
the weight reduction program on the level of malondialdehide (MDA) well established marker of lipid 
peroxidation and oxidative stress. Patients at the outpatient Clinic of the Department of Endocrinology, 
Diabetes and Metabolism disorders at the Dubrava University Hospital were enrolled in the weight reduc-
tion program involving diet and exercise. Participants received counseling and education during the ini-
tial week and were invited for the follow-up visits after one, three, six and twelve months. The plasma 
samples were collected at the initial visit and in one year period and were stored at -80 ºC. In plasma 
samples MDA level was assessed by the use of HPLC. Thirty fi ve obese patients enrolled in the weight 
reduction program participated in this preliminary study (age 47.9±12.4 (range 21 – 69); body weight 
109.2±15.3 kg (range 88.5 – 150 kg); 77.1% were woman). At the beginning of the study MDA level was 
4.08±1.7 μM (mean±SD). In one year follow-up, MDA level in the same group of patients was 2.71±0.9 μM, 
which was statistically lower from the level at the beginning of the study (p<0.05). Signifi cant decrease in 
a year period was also observed for the body weight (p<0.001) with the mean diff erence between initial 
and fi nal measurement being 5.5±6.5 kg. The results indicate that weight reduction program involving diet 
and exercise can reduce level of oxidative stress and consequently lead to healthier life.
55
Libri Oncol., Vol. 44 (2016), No 1, 27–56
P28: IN SEARCH OF NOVEL TRANS-ACTIVATORS OF X CHROMOSOME 
INACTIVATION
ADNA OMERAGIC, CHERYL MADURO, JOOST GRIBNAU
Department of Developmental Biology - Erasmus Medical Center, Rott erdam, The Netherlands 
(e-mail: adna.omeragic@gmail.com)
Dosage diff erences in X-linked gene expression between XY males and XX females are compensated 
in embryonic development of female mammals by the process of X chromosome inactivation (XCI). Prior 
to onset of XCI, determines the number of active X chromosomes and initiates XCI when more than one X 
chromosome is present per diploid genome. The master regulator region controlling XCI is the X inactiva-
tion center (Xic) that codes for a number of regulators of XCI that can have cis- or trans- mode of regula-
tion. Xist is a long non coding RNA (lncRNA) located at the Xic, is upregulated on the future inactive X, 
coating the X in cis, thereby recruiting a number of factors needed for silencing. X-linked, trans-acting 
regulators are expressed in a dosage dependent manner and enable female specifi c XCI initiation. Previ-
ous work in our lab has identifi ed a trans-acting activator, Rnf12, and obtained insights in its involvement 
in XCI. However, there is evidence that Rnf12 is not the sole activator of XCI since its deletion on one allele 
of the X chromosome in female cells, does not abolish XCI completely. In this project we sought to identify 
other putative activators of XCI. A 50Mb of X chromosomal region, located in the vicinity of the Xic locus, 
telomeric to Xist was deleted using the CRISPR/Cas9 system. Smaller deletions of 10Mb and 20Mb inside 
this 50Mb region were also performed to refi ne this 50Mb region. Targetings were performed in a reporter 
cell line that has GFP and mCHERRY transgenes under control of the endogenous Xist and Tsix promot-
ers, respectively. This way we have a reporter system to study the eff ect and activity of Rnf12 and newly 
identifi ed regulators throughout the XCI process. A successful deletion of the 50Mb region in the total cell 
pool, after targeting was detected. In addition, a smaller 10Mb deletion inside the 50Mb region was also 
detected in the cell pool. By generating deletions in the vicinity of the Xic locus we can get closer to fi nding 
the genomic regions where remaining activators of the XCI initiation are precisely located. Following the 
generated deletions we can proceed with isolating the desired single cell clones to establish the desired ES 
cell lines. The impact of the deletions on the XCI process is still to be investigated.
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Telomeres are specialized structures found at the ends of eukaryotic chromosomes serving as guard-
ians of genome stability. Normal mammalian cells demonstrate limited growth capacity. Due to the DNA 
end replication problem and additional 5’-exonuclease activity, their telomeres are shortening during each 
subsequent division. When telomeres are critically shortened cell proliferation is permanently stopped, a 
phenomenon known as cellular senescence. While telomere shortening is a main molecular mechanism 
that limits growth of normal cells, telomere elongation is crucial for the maintenance of immortalization in 
tumor cells. Thus, structural and functional analysis of telomeres is very important for understanding of 
cell growth control, cellular senescence and processes of immortalization. It is very important to monitor 
a behavior of telomere sister chromatids as indicator of molecular processes on telomeres. Therefore, we 
monitored these processes during cell senescence using quantitative PNA-FISH method. Observed diff er-
ences between sister telomeres are larger and more frequent than this could be att ributed to creation of -3’ 
single stranded overhangs after the replication of DNA. Sister telomere signals demonstrate high regular-
ity in telomere variations which ensure reproducibility of results using this method. We consider that 
defi cient hybridization and/or complexity of telomere DNA suprastructure result in observed diff erences 
in telomere strands labeling.
